Merck ups filing pace for lung cancer, HCV drugs
This article was originally published in Scrip
Executive Summary
Merck disclosed on 12 January it plans to submit applications to the FDA under earlier-than-expected timelines for Keytruda (pembrolizumab) in lung cancer and regimen grazoprevir/elbasvir (MK-5172/MK-8742) in hepatitis C virus (HCV).